Bi-directional Sanger sequencing of MET is performed using PCR primers designed to target hotspot mutations in exons 14, 16, 17 and 19.
This assay detects MET mutations, which are detected in 5% of colon cancers, 10% of upper digestive systems, 5% of kidney tumors, and 3% of lung cancers. MET deregulation in lung cancer is associated with poor outcome and resistance to anti-EGFR therapy. Multiple antibodies against MET and small molecule MET-inhibitors are currently in clinical trials for the treatment of various cancer types.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.